NEWS
Paul Hastings Advises Jefferies, TD Cowen, Leerink Partners and Stifel as Joint Book-Running Managers for Spyre Therapeutics’ Public Offering
October 07, 2026
Paul Hastings LLP advised Jefferies, TD Cowen, Leerink Partners and Stifel as joint book-running managers and LifeSci Capital as passive book runner for Spyre Therapeutics’ (Nasdaq: SYRE) $350 million public offering. The underwritten public offering consists of 4,117,648 shares of common stock at a price of $85.00 per share. The underwriters also have the option to purchase an additional 617,647 shares of Spyre’s common stock in the public offering. The offering is expected to close on or about Oct. 7, 2026.
Equity Capital Markets co-head and Corporate Life Sciences co-chair Seo Salimi, partner Will Magioncalda and associate Jonah Berger-Cahn led the Paul Hastings team.
More details can be found here.
About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.